ROCHESTER, N.Y. (PRWEB) February 22, 2018
Murray L. Zucker, MD, a healthcare consultant and former Senior Medical Director for Optum Health Behavioral Solutions, has joined CHESS Health, a leading addiction and relapse prevention technology company.
“Murray’s experience as a physician executive with a national payer, together with his record of service as a provider, makes him an ideal fit as CHESS Health’s chief medical officer,” says Hans Morefield, chief executive officer of CHESS Health. “We are delighted to have him join our leadership team, and know he will help us make a difference in our efforts to bring innovation and technology to the field of substance abuse and addiction.”
Zucker joins CHESS from MLZ Consultants, where he brought his more than 20 years of medical leadership to advise a range of healthcare clients on health plans, medical devices, and other areas of healthcare management and delivery. Prior to starting his own firm, he was the Senior Medical Director for New Product and Innovation at Optum. He was a founder of Encino Institute and Pacific Health Associates, and served as a consultant for the California Medical Board and an Examiner for California Workers Compensation. He is a graduate of the University of Rochester School of Medicine and Dentistry, and completed his psychiatric residency at UCLA School of Medicine, where he continued as a faculty member of the UCLA Department of Psychiatry.
“When it comes to addiction treatment, the biggest challenges are getting those in need to treatment, keeping them in treatment, preventing relapse, providing support and connection, and generating data to measure success,” says Zucker. “Due to technological advances, digital innovation, and clinically tested methods of engagement and treatment, we can provide a solution to these challenges. A-CHESS is the platform that can accomplish those goals. I’m excited to be part of such a pioneering organization.”
About CHESS Health
CHESS Health creates innovative solutions designed at the intersection of science, technology and recovery. Founded by nationally recognized substance abuse researcher Dr. Dave Gustafson, CHESS developed A-CHESS, the leading evidence-based relapse prevention technology. By integrating A-CHESS into treatment plans, clinicians, case managers and coaches can best support those in recovery with access to predictive relapse analytics, condition-specific content and access to live support, reducing relapse by 50 percent while decreasing costs and saving lives. Founded in 2014, CHESS Health has quickly positioned itself as a leader in the mHealth space, receiving recognition from the Substance Abuse and Mental Health Services Administration’s National Registry of Evidence-based Programs and Practices (NREPP), the Journal of Substance Abuse and the Surgeon General. To learn more about CHESS Health and the A-CHESS platform, visit http://www.chess.health.